Inexpensive meningitis vaccine could stop epidemics in Africa

06/16/2011 | Reuters

An inexpensive meningitis vaccine developed by generic-drug maker Serum Institute with funding from the Bill & Melinda Gates Foundation performed "dramatically better" than older vaccines, according to two studies published in the New England Journal of Medicine. Four weeks after receiving the first dose, 96% of patients who received MenAfriVac had a high antibody level, compared with 64% of patients who received an older vaccine. MenAfriVac costs about 50 cents per dose and is designed to protect against meningitis A.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX